funder-graph

FundersWA

Grants paid by Canine Cancer Research Alliance

EIN 82-3762441 · Bellevue, WA · Form 990, Schedule I · NTEE D12

Canine Cancer Research Alliance of Bellevue, WA (EIN 82-3762441) reported 12 grants paid totaling $768,384 to 8 recipients in tax years 2022–2024, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.

Grants paid

$768,384

12 grants

Recipients

8

distinct organizations

Tax years

2022–2024

3 filings in the corpus

By tax year

Grants by tax year, as the same figures
Tax yearGrants paidAmount paidApproved for future
20224$183,884
20234$335,000
20244$249,500

Top recipients

The 8 recipients receiving the most from Canine Cancer Research Alliance, by grants paid, out of 8 distinct recipients.

Recipients ranked by total grants paid
RecipientMatchLocationGrantsTotal paidLatest year
Yale University School of Medicine 06-0646973ANew Haven, CT3$360,0002024
Oregon State University Foundation 93-6022772ACorvallis, OR2$195,0002024
University of Illinois Foundation 37-6006007AUrbana, IL1$46,4002022
Therajan LLC 87-3925220ANew Haven, CT2$42,0002023
Ohio State University Foundation 31-1145986AColumbus, OH1$40,0002023
North Carolina University Veterinary Medical Foundation 56-6000756ARaleigh, NC1$35,4842022
Colorado State University Foundation 23-7098397AFort Collins, CO1$25,0002024
Dartmouth College Geisel School of Medicine 02-0222111ALebanon, NH1$24,5002024

Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.

Every grant

All 12 grant rows this organization reported, most recent first.

Grants reported by Canine Cancer Research Alliance
Tax yearRecipientMatchAmountTypePurposeSource filing
2024Yale University School of Medicine New Haven, CTA$110,000paidCANINE CANCER IMMUNOTHERAPY RESEARCH AND CLINICAL TRIAL FOR THE EGFR/HER2 CANCER VACCINE AND COMBINATION THERAPY EVALUATION.202543209349300159
2024Oregon State University Foundation Corvallis, ORA$90,000paidRESEARCH STUDYING THE IMPACT OF GUT MICROBIOME AND CANINE CANCER IMMUNOTHERAPY RESPONSE.202543209349300159
2024Colorado State University Foundation Fort Collins, COA$25,000paidPRE-CLINICAL RESEARCH INTO THE ROLE CANCER-ASSOCIATED FIBROBLASTS PLAY IN CANINE HEMANGIOSARCOMA METASTASIS.202543209349300159
2024Dartmouth College Geisel School of Medicine Lebanon, NHA$24,500paidCANINE CANCER RESEARCH FOCUSING ON COMBINATION INTRATUMORAL IMMUNOTHERAPY CLINICAL STUDY AND ASSOCIATED BIOMARKER ANALYSIS.202543209349300159
2023Yale University School of Medicine New Haven, CTA$160,000paidCANINE CANCER IMMUNOTHERAPY RESEARCH (EGFR/HER2 VACCINE AND EVALUATING AND ENHANCING ITS EFFICACY)202403199349301140
2023Oregon State University Foundation Corvalis, ORA$105,000paidRESEARCH AND CLINICAL TRIAL INVESTIGATING THE ROLE GUT MICROBIOME PLAYS IN CANCER IMMUNOTHERAPY TREATMENT. DEVELOPMENT OF NEW STRATEGIES TO IMPROVE TREATMENT EFFICACY.202403199349301140
2023Ohio State University Foundation Columbus, OHA$40,000paidRESEARCH ON DIETARY INTERVENTION (FASTING OR KETOGENIC DIET) ON THE TUMOR MICROENVIRONMENT AND TREATMENT EFFICACY FOR CANINE PATIENTS202403199349301140
2023Therajan New Haven, CTA$30,000paidTHERAPEUTIC VACCINE CLINICAL TRIAL FOR CANINE PATIENTS (HEMANGIOSARCOM, OSTEOSARCOMA, UROTHELIAL CARCINOMA)202403199349301140
2022Yale University School of Medicine New Haven, CTA$90,000paidResearch grant to develop safe and effective cancer immunotherapy. Determine the efficacy of EGFR/HER2 canine cancer vaccine through a clinical trial with canine patients. Explore strategies to enhance the patient response rate.202430439349300108
2022University of Illinois Foundation Urbana, ILA$46,400paidThe grant is to investigate the safety and efficacy of CAR-T therapy for dogs with aggressive sarcomas. Clinical trial will enrol dogs with hemangiosarcoma, osteosarcoma and recurrent soft tissue sarcoma.202430439349300108
2022North Carolina University Veterinary Medical Foundation Raleigh, NCA$35,484paidThis grant will determine the efficacy of canine cancer immunotherapy treatment for dogs with transitional cell carcinoma (TCC). Patients with bladder cancer with BRAF positive mutation will be enrolled and monitored with molecular tests (urine tests) for cancer progression.202430439349300108
2022Therajan LLC New Haven, CTA$12,000paidThis grant supports clinical trial, regulatory approval and commercialization of new canine cancer immunotherapy for dogs with solid tumors.202430439349300108

Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.

Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.

Source filings

Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.

Returns this page is derived from
FormTax yearPeriod endFiledSchemaIRS OBJECT_ID
99020242024-12-31not stated2024v5.0202543209349300159
99020232023-12-31not stated2023v5.0202403199349301140
99020222022-12-31not stated2022v5.0202430439349300108

Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/823762441.json.

The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.

This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.